- VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity
- VIVUS to Present at Upcoming Investor Conference
- VIVUS Announces Favorable Formulary Positioning for Qsymia
- VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia
- VIVUS Reports Third Quarter 2014 Financial Results
Latest EventsThere are currently no upcoming events
A Growing Pipeline
VIVUS is developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health.